Study on Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Advanced Parkinson's Disease
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
2,000estimated
Sites
4
Countries
Austria, Netherlands, Romania +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-14 | actual | When the study began enrolling |
| Primary completion | Dec 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Parkinson's Disease
Primary outcomes
what the primary-completion date above is the date OFMean Base Infusion Rate
measured Through end of optimization period (defined as no additional dose modification for at least 15 days since the last dose modification).
Mean Low Infusion Rate
measured Through end of optimization period (defined as no additional dose modification for at least 15 days since the last dose modification).
Mean High Infusion Rate
measured Through end of optimization period (defined as no additional dose modification for at least 15 days since the last dose modification).
Publications
- PMID 42322391 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed